

## **POLICY Document for AMONDYS 45 (casimersen)**

The overall objective of this policy is to support the appropriate and cost-effective use of the medication, specific to use of preferred medication options, lower cost site of care and overall, clinically appropriate use. This document provides specific information to each of the three sections of the overall policy.

### **Section 1: Site of Care**

- Policy information specific to site of care (outpatient, hospital outpatient, home infusion)

### **Section 2: Clinical Criteria**

- Policy information specific to the clinical appropriateness for the medication

### **Section 1: Site of Care**

## **Site of Care Criteria Amondys 45**

### **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated.

<b>Brand Name</b>	<b>Generic Name</b>	<b>Dosage Form</b>
Amondys 45	casimersen	intravenous

## **Criteria For Approval For Administration In Outpatient Hospital Setting**

This policy provides coverage for administration of Amondys 45 in an outpatient hospital setting for up to 45 days when a member is new to therapy or reinitiating therapy after not being on therapy for at least 6 months.

This policy provides coverage for administration of Amondys 45 in an outpatient hospital setting for a longer course of treatment when ANY of the following criteria are met:

- The member has experienced an adverse reaction to the drug that did not respond to conventional interventions (eg, acetaminophen, steroids, diphenhydramine, fluids, other

pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion.

- The member is medically unstable (eg respiratory, cardiovascular, or renal conditions).
- The member has severe venous access issues that require the use of special interventions only available in the outpatient hospital setting.
- The member has significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver.
- Alternative infusion sites (pharmacy, physician office, ambulatory care, etc.) are greater than 30 miles from the member's home.
- The member is less than 14 years of age.

For situations where administration of Amondys 45 does not meet the criteria for outpatient hospital infusion, coverage for Amondys 45 is provided when administered in alternative sites such as physician office, home infusion or ambulatory care.

## **Required Documentation**

The following information is necessary to initiate the site of care prior authorization review (where applicable):

- Medical records supporting the member has experienced an adverse reaction that did not respond to conventional interventions or a severe adverse event during or immediately after an infusion
- Medical records supporting the member is medically unstable
- Medical records supporting the member has severe venous access issues that requires specialized interventions only available in the outpatient hospital setting
- Medical records supporting the member has behavioral issues and/or physical or cognitive impairment and no access to a caregiver
- Records supporting alternative infusion sites are greater than 30 miles from the member's home
- Medical records supporting the member is new to therapy

## **Section 2: Clinical Criteria**

# **Speciality Guideline Management Amondys 45**

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Amondys 45	casimersen

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications<sup>1</sup>

Amondys 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with Amondys 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Initial requests:
  - Laboratory confirmation of Duchenne muscular dystrophy (DMD) diagnosis with a DMD gene mutation that is amenable to exon 45 skipping (refer to examples in Appendix).
  - If applicable, medical records confirming a worsening in clinical status since receiving gene replacement therapy.
- Continuation of therapy requests: documentation (e.g., chart notes) of response to therapy.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of Duchenne muscular dystrophy (DMD).

## Coverage Criteria

### Duchenne Muscular Dystrophy<sup>1,2</sup>

Authorization of 6 months may be granted for treatment of DMD when all of the following criteria are met:

- Genetic testing was conducted to confirm the diagnosis of DMD and to identify the specific type of DMD gene mutation.
- The DMD gene mutation is amenable to exon 45 skipping (refer to examples in Appendix).
- Treatment with Amondys 45 is initiated before the age of 14.
- Member is able to achieve an average distance of at least 300 meters while walking independently over 6 minutes.
- Member meets one of the following criteria:
  - Member has not previously received gene replacement therapy for DMD (e.g., Elevidys).
  - Member has previously received gene replacement therapy for DMD (e.g., Elevidys) and has experienced a worsening in clinical status since receiving gene replacement therapy (e.g., decline in ambulatory function).
- Member will not exceed a dose of 30 mg/kg once weekly.

## Continuation of Therapy

Note: Members who were previously established on Amondys 45 and subsequently administered gene replacement therapy (e.g., Elevidys) must meet all initial criteria prior to re-starting Amondys 45.

Authorization of 12 months may be granted for members requesting continuation of therapy when all of the following criteria are met:

- The member has demonstrated a response to therapy as evidenced by remaining ambulatory (e.g., able to walk with or without assistance, not wheelchair dependent).
- The member will not exceed a dose of 30 mg/kg once weekly.

## Appendix<sup>3,4</sup>

Examples of DMD gene mutations (exon deletions) amenable to exon 45 skipping (not an all-inclusive list):

- Deletion of exon 44
- Deletion of exon 46-47
- Deletion of exon 46-48
- Deletion of exon 46-49

- Deletion of exon 46-51
- Deletion of exon 46-53
- Deletion of exon 46-55

## REFERENCES

### SECTION 1

1. Amondys 45 [package insert]. Cambridge, MA: Sarepta Therapeutics Inc; July 2024

### SECTION 2

1. Amondys 45 [package insert]. Cambridge, MA: Sarepta Therapeutics; March 2023.
2. ClinicalTrials.gov. Study of SRP-4045 and SRP-4053 in DMD patients (ESSENCE). Available at: <https://clinicaltrials.gov/ct2/show/NCT02500381>. Accessed March 1, 2021.
3. Fletcher, S., et. al. Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative Splicing. The American Society of Gene & Cell Therapy. 2010;18(6):1218-1223.
4. Polavarapu K, Preethish-Kumar V, Sekar D, et al. Mutation pattern in 606 Duchenne muscular dystrophy children with a comparison between familial and non-familial forms: a study in an Indian large single-center cohort. J Neurol. 2019;266(9):2177-2185.